摘要
目的探讨(化疗)耐药蛋白LRP、与促瘤因素EGFR、HER-2在乳腺癌组织中的表达及其临床意义。方法采用免疫组化EnVision法,检测76例乳腺癌组织中LRP、EGFR、HER-2的表达。结果①在乳腺癌组织中,LRP、EGFR、HER-2的表达率分别为35.53%、15.79%、25%,相互之间表达相关性不明显。②随着肿瘤组织恶性程度的增高,LRP的表达明显降低(P=0.039)。③LRP、EGFR、HER-2在淋巴结非转移组与转移组中的表达无显著性差异。结论LRP的表达在乳腺癌的恶性进展过程中起重要作用,诊断过程中结合该指标可更准确判断肿瘤恶性程度。
Objective To investigate expression of LRP and EGRR, Her-2 in carcinoma of the breast, and evaluate its clinical significance.Methods Methods Seventy six cases of the besast carcinoma were detected by innnunlhistochemical techinque.Results ①The positive ratio of LRP, EGFR, HER-2 was 35.53 %, 15.79 %, 25 %. Their interaction was not distinct. ② The expression of LRP was significantly lower correlated with the rise of tumor grade. ③The expresssion of LRP,EGFR,HER-2 wes not connection with lymph node raetastasis.Concludion Expressions of LRP play an import role in the malignant progression of the Breast,and could be used to judge the grade of breast cancer.
出处
《中国实验诊断学》
北大核心
2009年第2期202-204,共3页
Chinese Journal of Laboratory Diagnosis
